Another commonly cited receptor is the epidermal growth factor receptor (EGFR), with approximately 30% of gliomas expressing the mutant EGFR—EGFRvIII.26 There have been numerous attempts to target the aberrant receptor using monoclonal antibodies and small-molecule inhibitors.27 In 2009, Bullain et al. developed genetically engineered T cells expressing a chimeric T cell receptor that targeted EGFRvIII.28 Their construct included a tumor antigen binding domain, transmembrane linker, and a cytoplasmic T cell receptor signaling domain (CD3 zeta). The gene discussed is EGFR; the disease is central nervous system cancer.